Chile’s ESKD treatment market is steadily expanding, supported by a robust public healthcare system (FONASA) and a high prevalence of diabetes and hypertension, which are primary contributors to chronic kidney disease. With over 20,000 dialysis patients, the country has a well-regulated nephrology network primarily centered in urban regions.
Key drivers include comprehensive public coverage for dialysis under the AUGE health plan, strong participation from private healthcare providers, and a relatively high level of health literacy among the population. Chile also boasts a strong record in early CKD detection through primary care programs.
However, access to dialysis and transplant services in rural or remote areas remains limited. Additionally, the country struggles with organ donation shortages, and long waitlists for kidney transplants continue to strain the system.
Trends include a shift toward home dialysis modalities such as peritoneal dialysis, the adoption of digital health records to streamline care coordination, and pilot programs involving AI to predict CKD progression. Chile is also seeing growing interest in eco-friendly dialysis systems to reduce water and energy usage.
Opportunities lie in expanding dialysis centers outside major cities, boosting public education on organ donation, and investing in domestic production of dialysis supplies to reduce dependence on imports. With a tech-savvy healthcare environment and government commitment to universal coverage, Chile offers a stable and progressive market for ESKD innovation.
TABLE - Chile End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By Treatment Type 2021-2033
Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Hemodialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Peritoneal Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Kidney Transplantation | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Deceased Donor Transplant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Living Donor Transplant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Medications & Supportive Care | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Immunosuppressants | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Erythropoiesis-Stimulating Agents (ESA) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Phosphate Binders | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Chile End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By Modality 2021-2033
Modality | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In-Center Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Home Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Chile End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By End-User 2021-2033
End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospitals & Clinics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Dialysis Centers | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Homecare Settings | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Research & Academic Institutes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Others | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis